Matwings Technology showcases its innovative AI-guided protein engineering techniques through the GenSci148 program, which aims to revolutionize therapeutic development.

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an...

人工知能（AI）を活用したたんぱく質設計を手がける中国スタートアップ企業「天鶩科技（Matwings Technology）」がこのほど、プレシリーズAで数千万元（数億〜十数億円）を調達した。出資は金沙江聯合資本（GSR United Capital）が主導し、本草資本（3E Bioventures）、暁池資本、四川交研資本も参加。資金は、たんぱく質設計に使う大規模言語モデル（LLM）の産業活用

Matwings Technology has successfully raised tens of millions in Series A funding to enhance its AI-driven protein design platform, AccelProtein™.

'Beyond Structure, Predicting Function' SHANGHAI, Dec. 25, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds,…